Home

SJIA Foundation

Systemic Juvenile Idiopathic Arthritis - Arthritis Foundatio

Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in kids and teens. About 10% - 20% of children with JIA have a rare and serious subtype called systemic juvenile idiopathic arthritis (SJIA). Systemic means it may affect not only the joints but other parts of the body, including the liver, lungs and heart This urgency inspired Rashmi Sinha and Jonathan Boutelle to found the Systemic JIA Foundation in 2015, three years after their son was diagnosed with systemic juvenile idiopathic arthritis (SJIA). SJIA is a serious and sometimes lethal childhood disease that can affect multiple organs. For many SJIA patients, the disease can be controlled with. Systemic JIA Foundation. 955 likes · 2 talking about this. The mission of the Systemic JIA Foundation (systemicjia.org) is to fund promising research & new treatment approaches in pursuit of a cure.. The SJIA Foundation has without a doubt saved my daughter's life. They are truly committed to their mission and work to help educate and serve the SJIA community. When my daughter was diagnosed with the life threatening complication MAS in June 2019 they worked quickly to get me valuable information and to put me in touch with doctors in.

Systemic JIA Foundation - Chan Zuckerberg Initiativ

Systemic JIA Foundation - Home Faceboo

Systemic Jia Foundation Reviews and Ratings Cincinnati

  1. Systemic Juvenile Idiopathic Arthritis. Systemic juvenile idiopathic arthritis (sJIA) only accounts for approximately 10% of all types of JIA, but has a disproportionately high morbidity compared with other subtypes. In most children, the disease begins with a severe systemic illness, characterized by fever, rash, and arthralgia or frank.
  2. ent on areas of increased warmth, such as under a child's shirt. Other things to watch for
  3. Learn more about the physical effects of SJIA, get words of wisdom for raising an independent child with SJIA and read about how one SJIA warrior copes through everyday life. https://bit.ly/3zJcj9o The content of this infographic was developed independently by the Arthritis Foundation, with production support from Novartis Pharmaceuticals.
  4. Prior exposure to cytokine inhibitors. Parenchymal lung disease and pulmonary hypertension complicating sJIA was first highlighted in a series of 25 cases reported by Kimura et al. in 2013. These authors raised the question of the possible relationship of this and the increasing use of anti-IL-1 and anti-IL-6 biologics in sJIA treatment

Morning: Zoo visit with SJIA Families JUNE 28th, FRIDAY (Pre-Conference) Afternoon: Group Discussion for families w/ Lung disease (by Invitation) Afternoon: Registration & Networking with SJIA Families Evening: SJIA Foundation Reception JUNE 29th, SATURDAY (Main Conference Program Foundation 6 provides you many different ways to style text. It's very flexible system that can give you the exact results that you want. Today we will be re..

Given the spread of Covid-19, we are regretfully postponing the SJIA Family Conference scheduled at the end of May. We are very disappointed but still hope to hold the conference at the end of summer.. Methods: A qualitative study of self-reported online survey of patients with SJIA was developed by the non-profit organizations, the Autoinflammatory Alliance, KAISZ/VAISZ, and SJIA Foundation in English and translated to Dutch. Respondents were recruited by convenience sampling through online social media posts Cure SJIA. 1,593 likes. CureSJIA supports the Systemic Juvenile Idiopathic Arthritis community through Awareness, Advocacy, & Education. Email: leah@systemicjia.or

We finally have the dates for SJIA Family conference - Friday May 29th to Saturday May 30th. We will be helping coordinate second opinion appointments and research participation for the SJIA patient.. Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability of interleukin-1 (IL-1) and IL-6 inhibitor treatment, morbidity has significantly reduced and the (long term) outcome for sJIA patients has improved over the last decade. However. Systemic Juvenile Idiopathic Arthritis (SJIA), is the rarest form of juvenile idiopathic arthritis, and it affects the entire body, including the joints. SJIA can occur any time during childhood, but it usually begins between the ages of 2 to 5, there is no known trigger for the disease. The most common presentation is a sudden onset of. In just a few days, she had Courtney's diagnosis, sJIA with possible complications from macrophage activation syndrome, or MAS. MAS is a potentially life-threatening complication common with rheumatic diseases that causes a massive systemic inflammatory response Dr. Henderson is studying systemic juvenile idiopathic arthritis (sJIA), a subtype of JIA. Many patients with sJIA initially present with fevers and rashes; a little more than half develop chronic arthritis that is difficult to treat. While it is known that inflammatory immune system cells play a role in the disease, it is not understood why.

Coping With Systemic Juvenile - Arthritis Foundatio

Novartis Arthritis Foundatio

Now, they have connected with dozens of families that have children with sJIA. The foundation is working closely with Schulert and Alexei Grom, MD, Director of Rheumatology Research at Cincinnati. Supported by the Systemic Juvenile Idiopathic Arthritis Foundation, the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K08-AR-072075 [to Dr. Schulert], R01-HL-085453 [to Dr. Trapnell], R01-AR059049 [to Dr. Grom], and P30-AR-070549), and a Cincinnati Children's Research Foundation ARC grant (to Drs. Schulert. HOW ARE PJIA & SJIA DIAGNOSED?3 There is no cure for PJIA or SJIA. The goals of treatment are to help relieve inflammation, control pain and improve your child's quality of life. Most treatment plans involve a combination of the following: HOW ARE PJIA & SJIA TREATED?3 References: 1. Arthritis Foundation. Juvenile Arthritis Objective: Systemic juvenile idiopathic arthritis (JIA) is associated with a recently recognized, albeit poorly defined and characterized, lung disease (LD). The objective of this study was to describe the clinical characteristics, risk factors, and histopathologic and immunologic features of this novel inflammatory LD associated with systemic JIA (designated SJIA-LD) A lifespan perspective on the disease (bringing together both parents of children with SJIA and adults with SJIA / Still's Disease) PRELIMINARY SPEAKERS LIST. Alexei Grom (Cincinnati Children's Hospital, USA) A. V. Ramanan (University of Bristol, UK) Bas Vastert (UMC Utrecht, Netherlands) Celinia Poli (Universidad del Desarrollo, Chile

SAJIDA Foundation Health, Happiness & Dignity for all

IBD in the setting of sJIA is a rare occurrence. The favorable response of sJIA symptoms to therapeutic TNF-α inhibition suggests that the sJIA-IBD cohort may represent a mechanistically distinct sJIA subgroup. Our study highlights the importance of maintaining a high level of suspicion for IBD when Funding This work was supported by the sJIA Foundation (EDM), the Lucile Packard Foundation for Children's Health (EDM), CARRA-Arthritis Foundation grant (EDM, VES), Life Sciences Research Foundation (GC), Bio-X Stanford Interdisciplinary Graduate Fellowship (JoB), Stanford Graduate Fellowship and the Computational Evolutionary Human Genetics. 6 SJIA Foundation, Cincinnati, USA. 7 Ospedale Pediatrico Bambino Gesù, Rome, Italy. 8 Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, USA. Alexi.Grom@cchmc.org

For the treatment of sJIA-associated lung disease that manifests as interstitial lung disease, such medications as cyclosporine, mycophenolate mofetil and abatacept may be options. But more data are needed to support these therapies. The Foundation is the largest private funding source for rheumatology research and training in the U.S Inclusion Criteria: - active sJIA disease according to ILAR criteria before screening and at baseline (Day 1); - Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted; - Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose.

Coping with Systemic Juvenile Idiopathic Arthritis

  1. Introduction. Systemic juvenile idiopathic arthritis (sJIA) is classified as a subtype of JIA, although it is increasingly recognized as a distinct disease 1-4.The ILAR classification criteria defines sJIA as arthritis in one or more joints, accompanied or preceded by systemic symptoms including quotidian fever of at least 2 weeks' duration, an erythematous rash, lymphadenopathy.
  2. Background: Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease associated with chronic arthritis. Early diagnosis and effective therapy of SJIA is desirable, so that complications are avoided. The PRO-KIND initiative of the German Society for Pediatric Rheumatology (GKJR) aims to define consensus-based strategies to harmonize diagnostic and therapeutic approaches in.
  3. REMINDER: Our hotline team is working remotely and focusing their time on helping our patients. We kindly ask pharmacies, providers, and their staff to use our Pharmacy and Provider Portals. Please note: if you are contacting us about a payment or grant, it is faster to email us at grants@healthwellfoundation.org.. We appreciate your continued patience and look forward to continuing to serve you

Systemic Juvenile Idiopathic Arthritis (SJIA), Stills Diseas

Valiyavila Foundation is a Registered Charitable Trust, Established by Dr. Joseph D. Fernandez, Reg. No. IV - 66 in 2001 and it has completed 20 years of its operations in various fields, mostly in education.There are nine trustees in this Trust who manage its operations.The Trust works in several villages of Kollam Read Mor MAS is a syndrome associated with Still's disease and some other auto-inflammatory diseases like HIDS/MKD that can lead to death. Tell your healthcare provider right away if your AOSD or SJIA symptoms get worse or if you have any of these symptoms of an infection: a fever lasting longer than 3 days. a cough that does not go awa Results. Of the patients with sJIA-IBD, 75% had a persistent sJIA course and 25% had a history of macrophage activation syndrome. sJIA-IBD subjects were older at sJIA diagnosis, more often non-White, had a higher rate of IBD family history, and were more frequently treated with etanercept or canakinumab compared to sJIA-only subjects SJIA/Still's Onset Stories. It came up with the Yahoo support group that is sponsored by the International Still's Disease Foundation. I sat and cried because of all the years of my loneliness. Then here was a group of others that had what I did and would understand my life / sJIA-associated lung disease. Articles tagged with sJIA-associated lung disease Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA. The Foundation is the largest private funding source for rheumatology research and training in the U.S

SJIA Family Conference 2019 - Systemic Juvenile Idiopathic

SJIA Foundation Mission - Rashmi Sinha - YouTub

Ningbo yinzhou sjia lab equipment co.,ltd. To better understand the pathogenesid of sjia and to facilitate the search for mas. Rashmi sinha speaking about the mission of the sjia foundation, and what parents, doctors, and researchers can do to help find. Sjia is de meest zeldzame vorm van juveniele idiopathische artritis (jia) ACR Issues sJIA Recommendations, SSc Classification Criteria. Two new documents from the ACR were released this October, representing the latest data and consensus about systemic juvenile idiopathic arthritis (sJIA) and systemic sclerosis (SSc). The first document, which details treatment options for sJIA, is the first update of the ACR's.

Video: SJIA: Systemic Juvenile Idiopathic Arthritis - Still's Diseas

Traditionally, sJIA had been treated with corticosteroids and NSAIDs, but the introduction of cytokine-targeting biologics some 15 years ago led to rapid, life-changing improvements in up to two. APPROVED USE. ILARIS ® (canakinumab) is a prescription medicine injected by your healthcare provider just below the skin (subcutaneous) used to treat Still's disease including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in children 2 years of age and older.. It is not known if ILARIS is safe and effective when used to treat SJIA in children under 2. Introduction. Systemic juvenile idiopathic arthritis (sJIA) is a chronic, inflammatory disease of childhood, observed worldwide, with an incidence of 0.4-0.9/100 000 in North America and Europe.1 A similar disease occurs in adults (adult-onset Still's disease (AOSD); incidence: 0.2-0.4/100 000).2 sJIA is characterised by a combination of arthritis, which can be destructive, and systemic. In Saper et al (2019), we described systemic JIA patients who developed a high-fatality diffuse lung disease (DLD) while on IL-1 or IL-6 inhibitors. We observed severe delayed drug hypersensitivity reactions (DHR) in a significant subset. Because alleles of the human leukocyte antigen (HLA) loci can mediate DHR, we investigated HLA genotype association with these DHR

Systemic Jia Foundation Cincinnati, OH Cause I

  1. A portion of the previous sales were combined with donations from other fundraisers in the community and matched by the Systemic JIA Foundation to form a larger donation to the pediatric Rheumatology department at Cincinnati Children's Hospital on July 22, 2017 during the first annual SJIA Family Education Day
  2. antly extra-articular manifestations like high fevers, rheumatic rash.
  3. Systemic juvenile idiopathic arthritis (sJIA) is an immune disorder characterized by fever, skin rash, arthritis and splenomegaly. Recently, increasing number of sJIA patients were reported having lung disease. Here, we explored lung abnormalities in a mouse model for sJIA relying on injection of IFN-γ deficient (IFN-γ KO) mice with complete Freund's adjuvant (CFA)
  4. Juvenile idiopathic arthritis (JIA) is a clinically heterogeneous group of arthritides that has been divided into categories in order to better understand pathogenesis and prognosis. By definition, the disease starts before 16 years of age and persists for longer than 6 weeks; however JIA has distinct disease categories that have different presentations and symptoms [1-3]
  5. FROST FROST (FiRst-line Options for Systemic JIA Treatment) Study Why This Is Important. Systemic juvenile idiopathic arthritis (sJIA) is a rare and aggressive form of childhood arthritis that can cause high fevers, rash, and other symptoms in addition to arthritis
  6. g complication

Next-Gen Therapies in SJIA & MAS - 2017 - Systemic

How the SJIA Foundation Plans to Reach every SJIA Family

  1. Guidance (Al-Hedayah) Foundation P.O. Box 84283, Lincoln NE 68501 Contact: Saeed Talebanfard, Abdul Lateef; New York. Howza Ilmiyya Jami'a Wali-ul-Asr P.O.Box 436, Medina, NY 14103 210-567-5993 Contact: Syed S. Hasan; Imam Al-Khoei Islamic Center 89-89 Van Wyck Expressway, Jamaica, NY 11435 Phone: (718) 297-6520 Contact: Muhsin M. R. Alidin
  2. The Arthritis Foundation and doctors in East Tennessee have shown great support and care for our daughter. We are thankful for the information the Arthritis Foundation has provided us and strive to be the best parents we can be for a child with SJIA. - Abby Williams, Aleaha's Mo
  3. Despite living with a serious, chronic illness, Georgia is an active first grader and enjoys soccer, T-ball, and playing with her dog Winter. She also enjoys art, including drawing and painting. Georgia is excited to be the youth honoree for northern New England so she can raise money for the Arthritis Foundation, and raise awareness of SJIA
  4. IL-1 inhibition in sJIA Pascual V et al JEM 201; 2005 Nigrovic P et al. Arthritis Rheum 63; 2011 5. Other IL1 inhibitors: Canakinumab (IL1 beta mAb) Ruperto N, et al. NEJM 367;25, 2012 6. IL6 inhibition in sJIA Tocilizumab (IL6r mAb) DeBenedetti F, et al. NEJM 367:25, 2012 7
  5. The Genentech Patient Foundation gives eligible patients their ACTEMRA free of charge. For more information, call a Foundation Specialist at (888) 941-3331 or visit GenentechPatientFoundation.com. †Other terms and conditions apply. ‡To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have.

Systemic juvenile idiopathic arthritis (SJIA) is a chronic autoinflammatory condition. The association with macrophage activation syndrome, and the therapeutic efficacy of inhibiting monocyte-derived cytokines, has implicated these cells in SJIA pathogenesis monary complication of SJIA. In her introduction, Dr. Sinha, the President of the Systemic JIA Foundation,stated that the longer-term goals of the meeting were to develop a strategy to enable the early diagnosis of SJIA-LD and im-prove the management of SJIA-LD, based on the current state of knowledge of this condition. The meeting in Patients with signs and symptoms of sJIA will be classified as outlined in #1, #2 and #3 below: 1. Patients less than 16 years of age will be considered to have sJIA if they meet the ILAR criteria for sJIA. 2. Patients 16 years of age and older will be considered to have sJIA if they have previously met ILAR criteria for sJIA. 3 Proceedings from NextGen Therapies for SJIA & MAS - 2019 Proceedings. Publication of this supplement has been supported by the SJIA Foundation. The article has undergone the journal's standard peer review process for supplements. CS is the Editor-in-Chief of Pediatric Rheumatology. No other competing interests were declared

Objective. We aimed to identify the (1) demographic/clinical characteristics, (2) medication usage trends, (3) variables associated with worse disease activity, and (4) characteristics of patients with persistent chronic arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry's systemic juvenile idiopathic arthritis (sJIA) cohort Funding: Cincinnati Children's Research Foundation Academic Research and Teaching (ARC) Grant. Severe lung disease associated with systemic juvenile idiopathic arthritis (SJIA-LD) Severe lung disease is a life-threatening complication of the autoinflammatory disorder systemic juvenile idiopathic arthritis (SJIA-LD) What is SJIA - How is it different than other diseases - Dr. Hermine Brunner. This talk was given by Dr. Hermine Brunner of Cincinnati Childrens Hospital to a group of patient families, at Systemic Juvenile Idiopathic Arthritis (or SJIA) Family Day on July 22nd, 2017. Systemic JIA Foundation

Proceedings from NextGen Therapies for SJIA & MAS - 201

  1. You may pay. $5 for each ACTEMRA treatment.*. You receive up to $15,000 every 12 months to help with your ACTEMRA drug costs. *The final amount owed by patients may be as little as $5, but may vary depending on the patient's health insurance plan. Eligible commercially insured patients who are prescribed ACTEMRA for an FDA-approved use can.
  2. Juvenile idiopathic arthritis (JIA), is the most common, chronic rheumatic disease of childhood, affecting approximately one per 1,000 children. Juvenile, in this context, refers to disease onset before 16 years of age, while idiopathic refers to a condition with no defined cause, and arthritis is inflammation within the joint.. JIA is an autoimmune, noninfective, inflammatory joint disease.
  3. SJIA affects about 10% of children with arthritis. Although symptoms can start at any time during childhood, SJIA symptoms generally emerge by elementary school years 2. The symptoms of PJIA and SJIA vary from person to person and can change on a daily basis. Symptoms may include: 1,2. SJIA symptoms may also include fever and rash
  4. In patients with systemic juvenile idiopathic arthritis (sJIA), it is often difficult for physicians to distinguish between infection and inflammatory disease activity. The purpose of this study is to see if two biomarkers, called CP and PCT, can help physicians identify when patients have an infection versus a flare of their sJIA. This study involves two study visits, one at the time of a.
  5. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. This service offers coverage support, patient assistance, and other useful information. Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine. Provides additional resources and information

IL-18 in sJIA IL-18 Potent activator of neutrophils Promotes Th1-type response (IFNg - MAS) Arthritis High circulating levels of IL-18 have been described in sJIA Correlation with several measures of articular inflammation and disease severity; potential biomarker of disease activity in sJIA Lotito et al, 2007 plasma Synovial fluid 17 Validation of the 2016 classification criteria for MAS showed that MAS was identifiable in cases of sJIA, with a sensitivity of 0.73 and a specificity of 0.99. AOSD is considered an adult counterpart of sJIA because both these conditions share clinical features, including high fever, rash, joint pain, and lymphadenopathy

Systemic Juvenile Idiopathic Arthritis - The Rheumatologis

The couple launched the Systemic JIA Foundation in 2017. Now, they have connected with dozens of families that have children with sJIA. The foundation is working closely with Schulert and Alexei Grom, MD, Director of Rheumatology Research at Cincinnati Children's, along with other medical centers, to help gather data on this alarming. The Genentech Patient Foundation. Gives free ACTEMRA to people who don't have insurance coverage or who have financial concerns and meet eligibility criteria. ‡ If you have health insurance, you should try to get other types of financial assistance, if available. You also need to meet income requirements. If you do not have insurance, or if your insurance does not cover your Genentech.

nextgen_2019_logo - Systemic Juvenile Idiopathic Arthritis

Expert Q&A: Recognizing Rashes in SJIA - Arthritis Foundatio

The global SJIA market is projected to grow at a rapid pace due to increase in prevalence of SJIA globally, also due to the available treatment and awareness between peoples are some other factors boosting the market growth. According to the Arthritis Foundation, nearly 3,000,000 children are suffering from SJIA in the U.S Weighted genetic risk scores were used to compare the genetic architecture of sJIA with other JIA subtypes. Results The major histocompatibility complex locus and a locus on chromosome 1 each showed association with sJIA exceeding the threshold for genome-wide significance, while 23 other novel loci were suggestive of association with sJIA Monocytes and macrophages in SJIA have a complex phenotype with both pro- and anti-inflammatory properties that combine features of Foundation and Procter Scholar Award from the Cincinnati Children's 2005;105(4):1648-1651. Research Foundation to G.S.S. 15. Maeno N, Takei S, Imanaka H, et al. Increased interleukin-18 expres- sion in bone. Objectives Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions unified by the presence of chronic childhood arthritis without an identifiable cause. Systemic JIA (sJIA) is a rare form of JIA characterised by systemic inflammation. sJIA is distinguished from other forms of JIA by unique clinical features and treatment responses that are similar to autoinflammatory diseases Unstoppable: Charcandrick West's Story. Charcandrick West has juvenile arthritis. Now he's dodging tackles in the NFL. It's a scene fans of the Kansas City Chiefs football team know well: Charcandrick West crashes into a tackler, spins and breaks free, then shifts into high gear as he races downfield. Yet Charcandrick, now in his fourth.

To determine whether systemic juvenile idiopathic arthritis (sJIA) susceptibility loci identified by candidate gene studies demonstrated association with sJIA in the largest study population assembled to date. Single nucleotide polymorphisms (SNPs One year ago today we arrived via air ambulance at Children's Hospital of Philadelphia (CHOP) with an incredibly sick child. We received a diagnosis of Systemic Juvenile Idiopathic Arthritis (SJIA) for GP within a short time of arriving. We're grateful for Dr. Burnham, the rheumatolgist who saved his life and his entire team at CHOP. Today we..

Diagnostic guidelines for MAS complicating sJIA and SLE exist [17-20]. Although these guidelines may be helpful, they have some limitations [ 21 - 23 ] including the fact that if MAS is the main first presenting feature, the patients' rheumatological diagnosis may still be unclear Methods: Parents or guardians of SJIA patients under 18 years of age, as identified through the CCHMC JIA database and Systemic JIA Foundation, were surveyed via mail or email, and responses stored in Research Electronic Data Capture. LD was divided into three subgroups of patients: interstitial lung disease (ILD) or pulmonary alveolar. Would you like to learn about research studies for SJIA / Still's that you can participate in (some are online)? Yes! No . Audio & Visual Release: By completing this registration form, you give the Systemic JIA Foundation permission to take and use your picture and/or videotape you,.

Julianna_medvaced - Systemic Juvenile Idiopathic Arthritis

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page.Assigned student editor(s): Thibault110583, Kplourde8.Assigned peer reviews: Cdoyon1, Msouza224, Sharrow96, Lee12201 Systemic juvenile idiopathic arthritis (sJIA) is an immune disorder characterized by fever, skin rash, arthritis and splenomegaly. Recently, increasing number of sJIA patients were reported having lung disease. Here, we explored lung abnormalities in a mouse model for sJIA relying on injection of IFN-γ deficient (IFN-γ KO) mice with complete Freund's adjuvant (CFA) To determine whether genetic variation within the MHC locus influences the risk of developing systemic juvenile idiopathic arthritis (sJIA), we examined a dense set of MHC region single nucleotide polymorphisms, classic HLA alleles, and the individual amino acids of HLA molecules in nine independent sJIA case-control populations. Association testing revealed that genetic variants within the.

NextGen17Logo - Systemic Juvenile Idiopathic ArthritisGetting Kineret-Anakinra approved by your insuranceNext gen therapies for SJIA & MAS Conference ProgramGenentech: Understanding PJIA & SJIAParents Advisory Board - Systemic Juvenile IdiopathicThe Hannah Sunshine FoundationThe Story of Ella - Systemic Juvenile Idiopathic Arthritis